DOXA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.685 SEK | +0.37% |
|
+2.87% | -21.15% |
| Apr. 29 | Doxa AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 10 | Doxa AB announced that it has received SEK 200 million in funding | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 5.3M 488K | Sales 2023 | 9.9M 912K | Capitalization | 1.74B 160M |
|---|---|---|---|---|---|
| Net income 2022 | -39M -3.59M | Net income 2023 | 292M 26.89M | EV / Sales 2022 | 259 x |
| Net cash position 2022 | 52.1M 4.8M | Net Debt 2023 | 94.6M 8.71M | EV / Sales 2023 | 186 x |
| P/E ratio 2022 |
-34.2
x | P/E ratio 2023 |
4.52
x | Employees | 6 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 39.11% |
More Fundamentals
* Assessed data
More news
More news
| 1 day | +0.93% | ||
| 1 week | +3.45% | ||
| Current month | +6.09% | ||
| 1 month | -4.76% | ||
| 3 months | -10.89% | ||
| 6 months | -25.82% | ||
| Current year | -20.70% |
1 week
2.61
2.77
1 month
2.482.88
Current year
2.483.60
1 year
2.485.50
3 years
2.4818.40
5 years
1.8318.40
10 years
1.0118.40
| Managers | Title | Age | Since |
|---|---|---|---|
Victor Persson
CEO | Chief Executive Officer | 40 | 21-12-31 |
Patrik Melin
DFI | Director of Finance/CFO | 47 | 21-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 64 | 20-12-31 | |
| Director/Board Member | 53 | 22-12-31 | |
Per Ekelund
CHM | Chairman | 53 | 20-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-13 | 2.685 | +0.37% | 539 268 |
| 24-05-10 | 2.675 | +0.75% | 358,579 |
| 24-05-08 | 2.655 | -1.48% | 293,644 |
| 24-05-07 | 2.695 | +3.26% | 902,050 |
| 24-05-06 | 2.61 | +0.38% | 1,261,132 |
Delayed Quote Nasdaq Stockholm, May 13, 2024 at 07:19 am EDT
More quotes
Doxa AB is a Sweden-based company which develops products based on bio-active ceramics. The Company develops, manufactures and commercializes products based upon its technology platform of calcium aluminate hydrate and bioactive ceramics. Activities are divided into the therapy areas of orthopedics and odontology. Research areas within orthopedics are methods for treating fractures resulting from osteoporosis, reconstructive orthopedics and coating of implants. Research areas within odontology are tooth restoration and implant fixation.
Calendar
2024-05-14
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -20.70% | 144M | |
| +12.14% | 29.29B | |
| +29.48% | 28.36B | |
| -7.64% | 25.5B | |
| +15.47% | 24.47B | |
| +44.75% | 23.83B | |
| +11.05% | 21.57B | |
| +2.90% | 19.32B | |
| +28.56% | 16.73B | |
| -1.82% | 15.96B |
- Stock Market
- Equities
- DOXA Stock
